Top 10 biosimilar companies | Suppliers & Manufacturers 2025

Top 10 biosimilar companies

This growth is driving the increasing demand for affordable biologic therapies, especially in oncology, autoimmune diseases, and diabetes. Patent expiration on some of the most important biologics is leading to more biosimilars receiving approval and acceptance in advanced and emerging market countries at an increasingly rapid pace.

Supportive regulatory changes, increased investments in biosimilar development, and increasing awareness of the benefits of biosimilars among healthcare providers are supporting the uptake of biosimilars across hospital, retail, and specialty pharmacy settings. Additionally, biopharma companies are pursuing strategic partnerships and increasing R&D to capture this emerging trend, while regulators are continuing to implement changes to further streamline the approval pathways to bring these products to market faster.

1. Samsung Bioepis

Samsung Bioepis is a joint venture focusing on developing and manufacturing biosimilars with advanced technology platforms. The company aims to provide affordable biologic treatments globally with a strong pipeline in oncology and autoimmune diseases.

2. Biocon Biologics

Biocon Biologics is a pioneer in biosimilars in India, developing cost-effective biologic therapies for diabetes, oncology, and autoimmune diseases. The company focuses on innovation, quality, and expanding access to affordable medicines globally.

3. Celltrion

Celltrion is a major player in the biosimilar market, offering biosimilars for treatments in autoimmune diseases and cancer. The company focuses on innovation and quality, with products approved in many countries worldwide.

4. Sandoz (a Novartis division)

Sandoz is a global leader in biosimilars, offering a broad portfolio of products that improve patient access to biologic therapies. As part of Novartis, it leverages extensive R&D capabilities to develop high-quality biosimilar medicines worldwide.

5. Zhejiang Hisun Pharmaceuticals

Hisun Pharmaceuticals is a leading Chinese biosimilar manufacturer focusing on oncology and immunology biosimilars. The company aims to become a global player by developing affordable, high-quality biosimilar products.

6. Pfizer Biosimilars

Pfizer is a leading pharmaceutical giant actively expanding its biosimilar portfolio. Their biosimilars target oncology, immunology, and other therapeutic areas, aimed at increasing access to affordable biologic treatments.

7. Fresenius Kabi

Fresenius Kabi specializes in biosimilars and generic injectable medicines, focusing on oncology and critical care. The company strives to enhance patient care by providing high-quality, affordable biologic therapies worldwide.

8. Mylan (now part of Viatris)

Mylan, now integrated into Viatris, has a strong biosimilar portfolio including treatments for cancer and autoimmune diseases. The company emphasizes expanding global access to biosimilars through innovation and partnerships.

9. Cipla Biosimilars

Cipla is a major Indian pharmaceutical company developing biosimilars for cancer and autoimmune diseases. Known for affordability and accessibility, Cipla aims to provide high-quality biosimilar medicines to emerging markets.

10. Amgen

Amgen is a global biotechnology leader with a growing biosimilar portfolio targeting cancer and chronic diseases. Their approach emphasizes scientific rigor, innovation, and patient access to advanced therapies.

Frequently Asked Questions About the Market Study (FAQs):